Dear Editor,
The need for platelet concentrates (PCs) is currently growing while the use of packed red blood cells is on the decline. PCs that are stored at room temperature (20-24 °C) provide a bacterial growth condition and are regarded as the main cause of bacterially induced transfusion disorders. 1 Recently, the antibacterial effects of several agents have been evaluated in platelets. 1, 2 Epsilon-Poly-L-lysine (ε-PLL) is a polypeptide composed of 27 to 33 identical L-lysine subunits, which was studied for the first time in Japan as an antimicrobial agent in PCs. 3 In the present study, PCs units were collected from healthy blood donors who visited the Blood Bank of Tehran (Iran) to determine the efficacy of the bactericidal activity of ε-PLL. Informed consent was obtained from all donors and the project was approved by the Research Ethics Committees of the Iranian blood transfusion organization.
The results indicated that the growth of S. epidermis, Pseudomonas aerugenosa, E. coli, and S. aureus in PCs was completely inhibited after 8 days of incubation with 100 µg/mL ε-PLL. There were no significant differences between the untreated controls and the PCs treated with ε-PLL in terms of the PCs quality variables (table 1). These findings are consistent with a previous report in Japan. In a study by Tanaka et al., 3 ε-PLL was found to inhibit the growth of the bacterial contaminants S. aureus, B. cereus, and K. oxytoca in the concentrations of 200 and 50 µg/mL in the plasma and PAS-IIIM PCs, respectively, after 8 days of incubation. Moreover, they demonstrated that ε-PLL did not significantly affect the quality of the PCs except for increased CD62P expression. The results of a study by Liu et al. 4 also showed the combination of ε-polylysine and nisin has synergistic antimicrobial activity against E. coli, B. subtilis, and S. aureus. Samadi et al. 5 investigated the antimicrobial activities of magnesium oxide nanoparticles and ε-PLL against two major foodborne bacteria, Escherichia coli O157:H7 and Listeria monocytogenes. They demonstrated the inhibitory effects of both substances. In a study by Zhao et al., 6 the amphiphilic e-poly-L-lysine (EPL)/poly (e-caprolactone) (PCL) copolymer showed a broad-spectrum antibacterial activity against Escherichia coli, Staphylococcus aureus, and Bacillus subtilis.
The main limitation of the present study was that the samples of each PCs were obtained on days 1, 3, 5, and 8 to determine the colony count of PCs inoculated with each bacterium. Thus, the trend of quality parameter changes was not studied. Consequently, more research on this topic is required prior to its application in clinical trials.
In conclusion, the presented data further support the proposal that ε-PLL inhibits the growth of the bacterial contaminants in room temperature stored platelets. Iran J Med Sci September 2017; Vol 42 No 5 Table 1 
